Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 8/20 | 0.60 |
| ▸ | ATR | Q13535 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839934 | 0.99 | ATM (0.61) | ATMATRHRH3KCNH2ADRA1A | |
| SCHEMBL20839523 | 0.88 | ATM (0.77) | ATMATRKCNH2MTOR | |
| SCHEMBL20839860 | 0.87 | HRH3 (0.52) | ATMATRHRH3KCNH2ADRA1A | |
| SCHEMBL20839262 | 0.86 | ATM (0.63) | ATMATRHRH3KCNH2ADRA1A | |
| SCHEMBL18824736 | 0.85 | ATM (0.81) | ATMATRKCNH2MTOR | |
| SCHEMBL20839257 | 0.85 | ATM (0.74) | ATMATRMTOR | |
| SCHEMBL18824613 | 0.84 | ATM (0.78) | ATMATRKCNH2MTOR | |
| SCHEMBL30972061 | 0.84 | ATM (0.58) | ATMATRKCNH2MTOR | |
| SCHEMBL20840080 | 0.83 | ATM (0.61) | ATMATRHRH3KCNH2ADRA1A | |
| SCHEMBL20839345 | 0.83 | ATM (0.52) | ATMATRHRH3KCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019057757-A1 | 1,3-DIHYDROIMIDAZO[4,5-C]CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-03-28 | — | — | WO | claimed |
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-08-17 | — | — | US | disclosed |
| EP-4171651-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | AstraZeneca UK Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021260580-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| WO-2019057757-A1 | 1,3-DIHYDROIMIDAZO[4,5-C]CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019057757-A1 | 1,3-DIHYDROIMIDAZO[4,5-C]CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ATM, CHEK2, ERBB2 | ATM 1/4885ATR 7/4885HRH3 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.